PubRank

T Dörner

Author PubWeight™ 59.12‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000 3.05
2 Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J Clin Invest 1997 2.44
3 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012 1.67
4 No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice. Rheumatology (Oxford) 2007 1.39
5 Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2007 1.36
6 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010 1.34
7 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008 1.31
8 HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2010 1.30
9 Pairing of variable heavy and variable kappa chains in individual naive and memory B cells. J Immunol 1998 1.20
10 Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011 1.19
11 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011 1.17
12 The human immunomodulatory CD25+ B cell population belongs to the memory B cell pool. Scand J Immunol 2007 1.16
13 Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000 1.11
14 Molecular mechanisms and selection influence the generation of the human V lambda J lambda repertoire. J Immunol 1999 1.10
15 Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. Lupus 2011 1.06
16 Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis 2003 1.05
17 Use of immunoglobulin variable-region genes by normal subjects and patients with systemic lupus erythematosus. Int Arch Allergy Immunol 2000 1.02
18 Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders. Ann Rheum Dis 2006 1.02
19 Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus 2008 1.01
20 Systemic lupus erythematosus after heavy exposure to quartz dust in uranium mines: clinical and serological characteristics. Lupus 1996 1.01
21 Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996 0.98
22 Validation of the sterilization procedure of allogeneic avital bone transplants using peracetic acid-ethanol. Biologicals 2001 0.98
23 Association of immunoglobulin-like transcript 6 deficiency with Sjögren's syndrome. Arthritis Rheum 2009 0.97
24 Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. Ann Rheum Dis 2008 0.96
25 Somatic hypermutation of VkappaJkappa rearrangements: targeting of RGYW motifs on both DNA strands and preferential selection of mutated codons within RGYW motifs. Eur J Immunol 1999 0.95
26 Enhanced mutational activity and disturbed selection of mutations in V(H) gene rearrangements in a patient with systemic lupus erythematosus. Autoimmunity 2000 0.94
27 Diagnosis of alveolitis in interstitial lung manifestation in connective tissue diseases: importance of late inspiratory crackles, 67 gallium scan and bronchoalveolar lavage. Lupus 1996 0.94
28 Efficient tetanus toxoid immunization on vitamin D supplementation. Eur J Clin Nutr 2011 0.93
29 CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation. Arthritis Rheum 2013 0.93
30 Immune hemolysis-serological and clinical aspects. Clin Exp Med 2003 0.93
31 Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008 0.89
32 Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome. Ann Rheum Dis 2008 0.88
33 Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i). Rheumatology (Oxford) 2008 0.87
34 Targeting and selection of mutations in human Vlambda rearrangements. Eur J Immunol 2000 0.87
35 Structurally derived mutations define congenital heart block-related epitopes within the 200-239 amino acid stretch of the Ro52 protein. Scand J Immunol 2005 0.87
36 Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the alpha and beta type. Arthritis Rheum 1999 0.87
37 Smaller role for pol eta? Nat Immunol 2001 0.86
38 Comparison of immunoglobulin heavy chain rearrangements between peripheral and glandular B cells in a patient with primary Sjögren's syndrome. Scand J Immunol 2003 0.85
39 The role of CD40-CD40 ligand (CD154) interactions in immunoglobulin light chain repertoire generation and somatic mutation. Clin Immunol 2001 0.85
40 Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls. Ann Rheum Dis 2001 0.85
41 The influence of CD40-CD154 interactions on the expressed human V(H) repertoire: analysis of V(H) genes expressed by individual B cells of a patient with X-linked hyper-IgM syndrome. Int Immunol 2000 0.84
42 Dissemination of a Sjögren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements. Arthritis Rheum 2006 0.84
43 Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 2000 0.82
44 [Recommendations for use of rituximab in patients with rheumatoid arthritis]. Z Rheumatol 2014 0.82
45 [Sjögren's syndrome. Current aspects from a rheumatological point of view]. Z Rheumatol 2006 0.82
46 Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 2013 0.82
47 Immunoglobulin Vkappa light chain gene analysis in patients with Sjögren's syndrome. Arthritis Rheum 2001 0.81
48 [Sjögren syndrome]. Internist (Berl) 2010 0.81
49 [Indications and options of new immune modulatory therapies for Sjögren's syndrome]. Z Rheumatol 2007 0.80
50 Antinuclear antibody- and extractable nuclear antigen-related diseases. Int Arch Allergy Immunol 2000 0.80
51 Complete heart block caused by primary Sjögren's syndrome and hypopituitarism. Ann Rheum Dis 1998 0.80
52 Immunoglobulin Vlambda light chain gene usage in patients with Sjögren's syndrome. Arthritis Rheum 2001 0.80
53 Similar characteristics of the CDR3 of V(H)1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells. Br J Haematol 1998 0.80
54 [Rituximab]. Z Rheumatol 2010 0.79
55 Anti-proteasome autoantibodies contribute to anti-nuclear antibody patterns on human larynx carcinoma cells. Ann Rheum Dis 2006 0.79
56 Diagnostic importance of anti-proteasome antibodies. Int Arch Allergy Immunol 2000 0.79
57 [Biosimilars : Current state of the build up to series production]. Z Rheumatol 2013 0.78
58 [Antiphospholipid syndrome 2007. Current aspects of laboratory diagnostics and their therapeutic consequences]. Z Rheumatol 2007 0.78
59 Progressive multifocal leukoencephalopathy in a patient with undifferentiated systemic vasculitis and bilateral acute retinal necrosis. Clin Exp Rheumatol 2009 0.77
60 Sufficient penetration of peracetic acid into drilled human femoral heads. Cell Tissue Bank 2005 0.77
61 Longlasting effects of immunoadsorption in severe Sjögren's syndrome. Ann Rheum Dis 2004 0.77
62 [Autoantibodies and antibody-secreting cells]. Z Rheumatol 2005 0.76
63 [Intrauterine therapy and outcome in four pregnancies of one mother with anti ro-autoantibody positive Sjoegren's syndrome]. Z Geburtshilfe Neonatol 2002 0.76
64 [Biologics therapy for systemic lupus erythematosus. Current situation]. Z Rheumatol 2015 0.75
65 [B-cell-directed therapy in patients with connective tissue diseases]. Dtsch Med Wochenschr 2012 0.75
66 [Translational aspects on the role of B-cells in autoimmune diseases. "From bench to bedside" and "from bed to benchside"]. Z Rheumatol 2009 0.75
67 Benefit of immunosuppression for severe Takayasu's arteritis and coincident primary biliary cirrhosis. Ann Rheum Dis 2004 0.75
68 [Sjogren-Syndrome. Current developments from a rheumatologists point of view]. Hautarzt 2008 0.75
69 [Current therapeutic options in Sjögren's syndrome]. Z Rheumatol 2010 0.75
70 [Successful therapeutic management of risk pregnancy in primary Sjögren syndrome with plasmapheresis and dexamethasone]. Z Rheumatol 1996 0.75
71 [Rheumatology on the move]. Dtsch Med Wochenschr 2002 0.75
72 Enhanced frequency of autoimmune congenital heart block in female offspring. Rheumatology (Oxford) 1999 0.75
73 Investigation of the anti-Ro autoantibody levels in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994 0.75
74 [Sjögren's syndrome]. Z Rheumatol 2010 0.75
75 [Personalized medicine for rheumatoid arthritis : serological and clinical patient profiles to optimize B and T cell targeted therapy]. Z Rheumatol 2013 0.75
76 A unique autoantibody pattern of positive anti-Jo-1, anti-U1RNP, and antiproteasome antibodies in autoimmune myositis as a diagnostic challenge. Ann Rheum Dis 2003 0.75
77 [Macrophage activation syndrome]. Z Rheumatol 2012 0.75